Vermact Plus 12 mg/400 mg Tablet is a combination of two antiparasitic medicines: Ivermectin and Albendazole. Ivermectin works by binding to the muscle and nerve cells of worms, causing their paralysis and death. Albendazole works by keeping the worms from absorbing sugar (glucose), so that the they lose energy and die. This treats your infection.
Vermact Plus 12 mg/400 mg Tablet may cause excessive drowsiness and calmness with alcohol.
WEIGH RISKS VS BENEFITS
Vermact Plus 12 mg/400 mg Tablet may be unsafe to use during pregnancy.
Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.
Vermact Plus 12 mg/400 mg Tablet is probably safe to use dur
Limited human data suggests that the drug does not represent a significant risk to the baby.
Vermact Plus 12 mg/400 mg Tablet may make you feel dizzy, sl
eepy, tired, or decrease alertness. If this happens, do not drive.
Vermact Plus 12 mg/400 mg Tablet is probably safe to use in
patients with kidney disease. Limited data available suggests that dose adjustment of Vermact Plus 12 mg/400 mg Tablet may not be needed in these patients. Please consult your doctor.
Vermact Plus 12 mg/400 mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Vermact Plus 12 mg/400 mg Tablet may be needed. Please consult your doctor.
Inform your doctor if you develop signs of jaundice like yellowing of eyes and skin, itching, and clay colored stools while taking this medicine.
What were the side-effects while using this medicine?
What are you using this medicine for?
Survey Participants: 1
“The following are the results of on-going survey on 1mg.com for Vermact Plus 12 mg/400 mg Tablet. These results only indicate the perceptions of the website users. Please base your medical decisions only on the advice of a doctor or a registered medical professional.”
Information last updated by Dr. Varun Gupta, MD Pharmacology on 25th Jan 2018.